Market revenue in 2024 | USD 106.4 million |
Market revenue in 2030 | USD 168.6 million |
Growth rate | 8% (CAGR from 2025 to 2030) |
Largest segment | Pacemakers |
Fastest growing segment | Ventricular Assist Devices |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Ventricular Assist Devices, Implantable Cardioverter Defibrillators, Pacemakers, Cardiac Resynchronization therapy, Counter Pulsation Devices |
Key market players worldwide | Medtronic PLC, Boston Scientific Corp, Abbott Laboratories, Jarvik Heart, ReliantHeart, Biotronik SE & Co., KG, Berlin Heart GmbH |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to congestive heart failure treatment devices market will help companies and investors design strategic landscapes.
Pacemakers was the largest segment with a revenue share of 42.11% in 2024. Horizon Databook has segmented the Australia congestive heart failure treatment devices market based on ventricular assist devices, implantable cardioverter defibrillators, pacemakers, cardiac resynchronization therapy, counter pulsation devices covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia congestive heart failure treatment devices market, including forecasts for subscribers. This country databook contains high-level insights into Australia congestive heart failure treatment devices market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account